Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Authors:
- Vivek SubbiahVSVivek Subbiah
- Mimi I. HuMHMimi I. Hu
- Aaron S. MansfieldAMAaron S. Mansfield
- Matthew H. TaylorMTMatthew H. Taylor
- Martin SchulerMSMartin Schuler
- Viola W. ZhuVZViola W. Zhu
- Julien HadouxJHJulien Hadoux
- Giuseppe CuriglianoGCGiuseppe Curigliano
- Lori WirthLWLori Wirth
- Justin F. GainorJGJustin F. Gainor
- Guzman AlonsoGAGuzman Alonso
- Douglas R AdkinsDADouglas R Adkins
Top Cited Papers
Open Access
- 16 January 2024
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 34 (1) , 26-40
Abstract
Background: Rearranged during transfection ( RET ) alterations are targetable oncogenic drivers in thyroid cancer. Primary data from the open-label, phase 1/2 ARROW study demonstrated clinical activity and manageable safety with pralsetinib, a selective RET inhibitor, in patients with advanced/metastatic RET -altered thyroid cancer. We present an updated analysis with more patients and longer follow-up. Methods: Adult patients with advanced/metastatic RET -mutant medullary thyroid cancer (MTC) or RET fusion-positive thyroid cancer who initiated oral pralsetinib at 400 mg once daily were included. Primary endpoints were overall response rate (ORR) by blinded independent central review (per RECIST v1.1) and safety. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), and overall survival. Responses were assessed in three cohorts of patients with baseline measurable disease: patients with RET -mutant MTC who had received prior cabozantinib and/or vandetanib (C/V), treatment-naïve patients with RET -mutant MTC, and patients with previously treated RET fusion-positive thyroid cancer. Patient-reported outcomes (PROs) were an exploratory endpoint. Results: As of October 18, 2021, the measurable disease population comprised of 61 patients with RET -mutant MTC and prior C/V, 62 treatment-naïve patients with RET -mutant MTC, and 22 patients with RET fusion-positive thyroid cancer who had received prior systemic therapy, including radioactive iodine. The ORR was 55.7% [confidence interval; 95% CI: 42.4–68.5] in patients with RET -mutant MTC and prior C/V, 77.4% [95% CI: 65.0–87.1] in treatment-naïve patients with RET -mutant MTC, and 90.9% [95% CI: 70.8–98.9] in patients with previously treated RET fusion-positive thyroid cancer. Median DoR and median PFS were both 25.8 months in patients with RET -mutant MTC and prior C/V, not reached in treatment-naïve patients with RET -mutant MTC, and 23.6 and 25.4 months, respectively, in patients with previously treated RET fusion-positive thyroid cancer. In the RET -altered thyroid cancer safety population ( N = 175), 97.1% of patients reported a treatment-related adverse event (TRAE); these led to discontinuation in 5.7% and dose reduction in 52.6% of patients. There was one death (0.6%) due to a TRAE. PROs improved or remained stable after pralsetinib treatment. Conclusions: In this updated analysis of the ARROW study, pralsetinib continued to show deep and durable clinical activity and a manageable safety profile in patients with advanced/metastatic RET- altered thyroid cancer. Clinical Trial Registration: NCT03037385Keywords
This publication has 22 references indexed in Scilit:
- Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer–Related Diarrhea and Its Effects on Quality of Life: A Pilot StudyThyroid®, 2015
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid CarcinomaThyroid®, 2015
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialThe Lancet, 2014
- Cabozantinib in Progressive Medullary Thyroid CancerJournal of Clinical Oncology, 2013
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Medullary thyroid carcinoma: The third most common thyroid cancer reviewedOncology Letters, 2010
- RET/PTC Rearrangements and BRAF Mutations in Thyroid TumorigenesisEndocrinology, 2007
- Prognosis of medullary thyroid carcinomaCancer, 2006
- Interpreting the significance of changes in health-related quality-of-life scores.Journal of Clinical Oncology, 1998
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993